Table 2 Features and treatment of patients with recurrent thrombotic or obstetric events
Pt | Age first event (years) | APS type | Triple + aPL | First event | Initial treatment | Time to recurrence (months) | Recurrent event | AC prescribed at time of recurrence | Adherence to AC treatment |
|---|---|---|---|---|---|---|---|---|---|
5 | 14 | 2°, Thr | Yes | Splenic infarctiona | LDA | 7.6 | Renal TMAb | LDA | Yes |
8 | 17 | 2°, Thr | Yes | Myocardial infarctionb | Fondaparinux and LDA | 80.5 | Cardiac thrombusd | LDA; apixaban recently discontinued | Yes |
11 | 16 | 1°, Thr | Yes | PE, lower extremity DVTc | Warfarin | 59.0 | Lower extremity DVTc | Warfarin | No (loss of health insurance) |
13 | 16 | 2°, Thr | No | Lower extremity DVTc | Warfarin (planned for 3 months) | 19.4 | Lower extremity DVTd | None | - |
62.1 | Lower extremity DVTd | Rivaroxaban | No (patient reported) | ||||||
14 | 18 | 2°, Obs | No | HELLP, Pre-eclampsia, thrombotic vasculopathy of placenta and skind | LMWH – prophylactic dose | 4.6 | Early pregnancy lossd | LMWH – prophylactic dose | Yes |
16 | 10 | 2°, Thr | No | CVA, renal infarctiond | LMWH | 23.4 | CVAd | LMWH | No (physician reported) |
18 | 12 | 1°, Thr | Yes | Liver lesions with small-vessel thrombotic vasculopathy d | LMWH | 3.0 | PEd | LMWH | No (family reported) |
19 | 15 | 1°, Thr | Yes | Lower extremity DVTc | LMWH transitioned to warfarin | 36.8 | Portal vein thrombosis d | Warfarin | No (physician reported) |
74.8 | CVAd | Warfarin | No (physician reported) | ||||||
20 | 17 | 1°, Thr | No | Lower extremity DVTc | LMWH | 2.0 | PEc | None (suspected medication interaction on LMWH) | - |
2.9 | PEc | Warfarin (subtherapeutic) transitioning to LMWH | Yes | ||||||
4.0 | PEd | LMWH | No (physician reported) | ||||||
11.6 | PE with secondary pulmonary infarctiond | Fondaparinux and LDA | Yes |